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Abstract
Background: The Risk of Bias (RoB) tool is used to assess internal validity of randomized controlled trials (RCTs). Our
objectives were to: 1) evaluate inter-rater agreement of the RoB tool; 2) determine the time to access supplemental study
information; 3) compare the RoB tool with the Jadad scale and Schulz allocation concealment (AC); and 4) examine the
relationship between RoB and effect estimates.
Methods: We conducted a systematic review of long-acting beta agonists (LABA) combined with inhaled corticosteroids
(ICS) for adults with persistent asthma. Two reviewers independently assessed 107 trials using RoB, Jadad, and AC. One
reviewer searched for study protocols. We assessed inter-rater agreement using weighted Kappa (k) and the correlation
between tools using Kendall’s Tau (t). Mean differences in effect sizes for RCTs with different RoB were calculated using
inverse variance method and random effects model.
Results: Trials had good Jadad scores (median 4, IQR 3-4);however, 85%hadunclearAC and 87% high RoB. The factor that most
influenced RoB was the potential inappropriate influence of study sponsors (95% industry funded). Agreement on RoB domains
was fair (k=0.40) toalmost perfect (k=0.86), and moderatefor overall RoB (k=0.41). Median time to complete RoB assessments
was 21 minutes (IQR 14-27) and 12 minutes (IQR 9-16)tosearchfor protocols.Protocols were identifiedfor 5/42 studies (12%);in3
cases the assessment of selective outcome reporting changed. There was low correlation between overall RoB vs. Jadad (t=0.04,
p=0.3) and AC (t=20.02, p=0.7). Analyses comparing effect estimates and risk showed no important patterns.
Conclusions: Inter-rater agreement on RoB assessments was better than previously reported suggesting that review-specific
guidelines are important. The correlation between RoB and Jadad was low suggesting measurement of different constructs
(risk of bias vs. quality of reporting). The extensive involvement of the pharmaceutical industry in this LABA/ICS research
should raise concerns about potential overestimates of treatment effects.
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Introduction
Assessing the methodological quality, or risk of bias, of studies
included in a systematic review (SR) is a key methodological step
and serves to identify the strengths and limitations of individual
studies; investigate, and potentially explain, heterogeneity in
findings across different studies included in a SR; and, contribute
to grading the quality of a body of evidence for a given question.
There are numerous tools to assess methodological quality of
primary studies; however, few have undergone extensive inter-
rater reliability or validity testing. It is unknown whether, or to
what extent, quality assessments based on existing tools differen-
tiate studies that may yield biased results either by over or
underestimating treatment effects. Such information is critical for
decision-making in order to gain an accurate assessment of the
potential benefits (or harms) of a given intervention.
In 2008, The Cochrane Collaboration released a new tool to
assess risk of bias in randomized controlled trials (RCTs) [1]. The
Risk of Bias (RoB) tool was developed through an extensive process
in order to improve on other tools used for quality assessment [1].
The RoB tool comprises six domains: sequence generation,
allocation concealment, blinding, incomplete outcome data,
selective outcome reporting, and ‘‘other sources of bias.’’ These
domains were chosen based on empirical evidence demonstrating
potential for bias or exaggeration of treatment effects. For instance,
numerous meta-epidemiological studies have demonstrated that
RCTs with inadequate or unclear allocation concealment can
overestimate treatment effects by 18% on average [2]. Table 1
identifies common sources of bias and the relevant domains of the
RoB tool that assess each bias. Further, the tool was intended to
assess the validity of results based on the features associated with the
design and conduct of the study, rather than reporting.
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agreement ranged from slight (k=0.13) to substantial (k=0.74)
across the different domains, with overall risk of bias assessment
being fair (k=0.27) [3]. The authors also provided preliminary
data showing validation of the RoB tool: studies at high or unclear
risk of bias had significantly greater treatment effects (effect
size=0.52) than those at low risk of bias (effect size=0.23). The
authors made recommendations for future research including:
evaluating the tool within the context of a SR with pilot testing and
established decision rules; quantifying time requirements when all
main outcomes are included in the assessment; examining time
requirements and impact on risk of bias assessments when
searching for study protocols or additional study information;
and, using a meta-epidemiological approach to assess validity in
order to minimize confounding due to intervention and design.
Building on this previous research, we applied the RoB tool to
a large SR examining combination long-acting beta-agonists
(LABA) and inhaled corticosteroids (ICS) for maintenance therapy
of persistent asthma [4]. We sought to: 1) assess inter-rater
agreement of the RoB tool following rigorous pilot testing and
review-specific decision rules; 2) assess the time to access supple-
mental study information and the impact of additional information
on risk of bias assessments; 3) compare the RoB tool with two
common approaches to quality assessment in SRs (Jadad scale [5]
and allocation concealment [6]); and, 4) examine the relationship
between risk of bias and effect estimates.
Methods
Study sample
The study sample was 107 RCTs that were included in a SR of
combination LABA/ICS for maintenance therapy in persistent
asthma. The median year of publication of these RCTs was 2004
(interquartile range [IQR] 2001, 2006). The methods of the SR,
reported in detail elsewhere [4], are briefly described here. A
comprehensive search of electronic databases and grey literature
were performed to avoid publication and selection bias. Studies
were included if they were RCTs involving the use of ICS/LABA
combination agents in the treatment of chronic asthma.
As part of the SR, all RCTs were assessed for methodological
quality independently by two reviewers using the Jadad scale [5]
and allocation concealment [6]. Jadad is a 5-point scale comprised
of items related to sequence generation, blinding, and withdrawals.
It is the most widely used and frequently cited quality assessment
instrument [7]. Allocation concealment has historically been used
alone or in conjunction with the Jadad scale and is rated as
adequate, inadequate, or unclear. Consensus on quality assess-
ments were made through discussion between the two reviewers or
adjudicated by a third reviewer. Data on effect estimates from
individual studies were extracted as part of the SR: data were
extracted by one reviewer and checked for accuracy and
completeness by a second reviewer. All data were checked by
the statistician during analysis.
Risk of bias assessments
We conducted pilot testing of the RoB tool among the team of
reviewers who would complete all risk of bias assessments. We
relied primarily on guidelines for application of the tool developed
by The Cochrane Collaboration [1]. For the ‘‘other sources of
bias’’ domain, we regularly looked for baseline imbalances
between study groups that could have biased the results or that
were not accounted for; inappropriate influence of funders that
could have biased the results; and early stopping for benefit. In
addition, we developed several decision rules to address nuances
specific to this SR, such as how to assess potential bias due to
influence of funders (Appendix S1).
Each study was assessed independently by two reviewers and
any discrepancies were resolved through discussion. The tool was
applied for three outcome categories: pulmonary function tests,
asthma control, and quality of life. For a sample of studies (40%),
one reviewer searched for supplemental information (i.e., trial
protocols) using a pre-defined protocol. This included searching
online trial registries (www.who.int/trialsearch, www.clinicalstu
dyresults.org, www.controlled-trials.com/mrct) and performing a
Google search using the name of the corresponding author, title,
and key words. For each study, reviewers documented the time
required to independently complete their RoB assessment,
complete consensus, and search for additional study information.
Analysis
Inter-rater agreement was calculated using weighted kappa (k)
statistics for each domain and for an overall RoB assessment.
Agreement was categorized based on published norms: poor
(0.00), slight (0.01–0.20), fair (0.21–0.40), moderate (0.41–0.60),
substantial (0.61–0.80), and almost perfect (0.81–1.00) [8].
Correlations between the RoB tool and the Jadad scale and
allocation concealment were calculated using Kendall’s tau (t). For
each risk of bias domain and for overall RoB, we compared effect
estimates for studies at high or unclear risk of bias vs. low risk of
bias. We calculated mean differences in effect size using an inverse
variance method and random effects model. A priori we planned
to compare effect estimates for pulmonary function tests (i.e.,
FEV1), asthma control (i.e., symptom-free days), and quality of life.
Due to insufficient quality of life data, we were unable to make
meaningful comparisons.
Table 1. A classification scheme for bias (based on Table 8.4.1 in Cochrane Handbook for Systematic Reviews of Interventions [1]).
Type of bias Description Relevant domains in the Risk of Bias tool
Selection bias Systematic differences between the baseline characteristics of the groups. Sequence generation
Allocation concealment
Performance bias Systematic differences between the groups in the care that is provided,
or in exposure to factors other than the interventions of interest.
Blinding
Other sources of bias
Attrition bias Systematic differences between groups in withdrawals from the study. Incomplete outcome data
Blinding
Detection bias Systematic differences between groups in how outcomes are measured. Blinding
Other sources of bias
Reporting bias Systematic differences between reported and unreported findings. Selective outcome reporting
doi:10.1371/journal.pone.0017242.t001
Application of the Risk of Bias Tool
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Overall methodological quality and risk of bias
The median Jadad score across the 107 RCTs was 4 on a five-
point scale (IQR 3, 4); scores greater or equal to 3 are considered
good methodological quality [9;10]. Allocation concealment was
unclear in 91 (85%) and adequate in 16 (15%) studies. Ninety-
three trials (87%) were at high risk of bias and 14 (13%) at unclear
risk of bias. No studies were assessed as low risk of bias. The factor
that was most influential for risk of bias was the potential for
inappropriate influence of the study sponsor. Overall 95% of these
LABA/ICS trials were funded by the pharmaceutical industry. In
35 studies (41%), the first or last author was affiliated with
industry. Further, in 84 studies (79%), one of the authors was an
employee of the pharmaceutical industry or the document was an
industry report. We recalculated risk of bias without the funding
component and found that 38 (36%) were high, 66 (62%) were
unclear, and 3 (3%) were low risk of bias.
Inter-rater agreement for risk of bias assessments
Inter-rater agreement (Table 2) varied across RoB domains. For
example, the agreement was fair (0.40) for selective outcome
reporting and almost perfect (0.86) for sequence generation. Inter-
rater agreement for the majority of domains and overall risk of bias
was moderate (k=0.41–0.60). Table 2 also compares the inter-
rater agreement to that found in a previous study demonstrating
improvement in all but one domain [3].
Time for risk of bias assessments and supplemental
information search
The average time for one reviewer to complete the risk of bias
assessment was 8.7 minutes per study (IQR 5.9, 11.4). The average
time required for consensus between two reviewers was 1.5
minutes per study (IQR 0.5, 2.5). Overall time required for two
reviewers to complete assessments and consensus was 20.5 minutes
per study (IQR 14.4, 27.0). The average time spent searching for a
study protocol or other supplemental study material was 11.7
minutes (IQR 9.1, 15.6). Supplemental study material was found
for 5/42 (12%) of the trials. In 3/5 cases, assessment of selective
outcome reporting changed, although the direction of changes was
inconsistent: unclear to yes, yes to unclear, and unclear to no.
Correlation of risk of bias and quality assessments
Tables 3 and 4 display the assessments for RoB compared to
Jadad scores and allocation concealment, respectively. The
correlations between overall risk of bias assessments and total
Jadad score (t=0.04) and allocation concealment (t=0.02) were
low. When the funding component was removed from the overall
risk of bias assessments, the correlations remained low (t=0.17 vs.
Jadad and 0.07 vs. allocation concealment).
Association between risk of bias and effect estimates
Figures 1 to 4 show the differences in effect estimates for studies
at different risk of bias for each of the domains in the RoB tool as
well as overall risk of bias, both with and without ‘‘other’’ sources
of bias. Figures 1 and 3 compare high or unclear vs. low risk of
bias, while Figures 2 and 4 compare high vs. unclear or low risk of
bias. There were few notable differences observed which may be
due to the homogeneity of study results in this review and small
differences in effects within the original meta-analyses [4]. The one
difference observed that may be of clinical importance is larger
treatment effects for trials at high or unclear risk compared to
those at low risk with a difference of 12 symptom-free days
(Figure 3, other sources of bias).
Discussion
This study examined the reliability of the RoB tool and
compared this tool with other quality assessment tools currently
employed in SRs. We demonstrated improved reliability for risk of
bias assessments using the new RoB tool compared to previous
research [3]. This may be due to the fact that this study was based
on RCTs included in a real SR hence there was more consistency
across trials with respect to a number of factors including
populations, interventions, control interventions, outcomes, study
design, and reporting. In contrast, the previous research was based
on a sample of diverse pediatric trials that covered numerous
interventions and conditions [3]. The improved reliability may
also have stemmed from rigorous pilot testing, training of
Table 2. Inter-rater agreement for individual domains and
overall risk of bias.
Domain
Weighted kappa
(95% CI) Interpretation
Previous
research (3)
Sequence generation 0.86 (0.74, 0.98) Almost perfect Substantial
Allocation concealment 0.54 (0.29, 0.79) Moderate Moderate
Blinding 0.62 (0.46, 0.79) Substantial Fair
Incomplete data 0.44 (0.27, 0.62) Moderate Fair
Selective reporting 0.40 (0.14, 0.67) Fair Slight
Other sources of bias 0.52 (0.33, 0.72) Moderate Fair
Overall risk 0.41 (0.19,0.62) Moderate Fair
doi:10.1371/journal.pone.0017242.t002
Table 3. Assessment of risk of bias vs. Jadad scores (n=107
trials; correlation, t=0.04).
Jadad Scores
Good quality
(score $3)
Poor quality
(score ,3)
Risk of bias
Low 0 0
Unclear 13 1
High 82 11
doi:10.1371/journal.pone.0017242.t003
Table 4. Assessment of risk of bias vs. allocation concealment
(n=107 trials; correlation, t=0.02).
Allocation concealment
Adequate Unclear Inadequate
Risk of bias
Low 0 0 0
Unclear 3 11 0
High 13 80 0
doi:10.1371/journal.pone.0017242.t004
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of decision rules specific to the SR.
The overall time required to complete the risk of bias
assessments in this study was consistent with time reported in
previous research [3]. In the present study, however, risk of bias
was assessed for three clinically important outcome categories for
the review, whereas the previous study assessed risk of bias for only
one outcome. This suggests that time required by outcome may
have decreased.
The time spent searching for supplemental study information,
including the study protocol, added substantially (50%) to the total
time for the risk of bias assessments. While the yield from these
searches provided additional information in only 12% of studies,
the additional information did result in differences in assessment of
selective outcome reporting in 3 of the 5 cases. The potential for
supplemental information to change assessments raises several
items for consideration, especially as it pertains to selective
outcome reporting. First, relying on the published or final trial
report may not result in accurate assessment of selective outcome
reporting. Second, since a substantial amount of time is required
to systematically search for additional information, based on this
study, the yield may not be worth the resource investment. We
conducted a comprehensive search of various sources for
supplemental study information and believe that the low yield
was not due to insufficient searching but to a lack of availability of
trial protocols and the inherent difficulties in searches of the grey
literature. Since the median year of publication for our trials was
2004, recent initiatives such as universal trial registration and the
Standard Protocol Items for Randomized Trials (SPIRIT)
initiative may improve this in the future [11;12].
The low correlation between overall risk of bias assessments and
total Jadad score was confirmed in this study. This may reflect the
different domains included across the tools; however, the fact that
different tools derive such divergent overall estimates of the quality
or risk of bias of a body of literature is troublesome, particularly for
decision-makers. Based on the Jadad scale, this sample of trials
would be considered of good methodological quality. The RoB
assessments, however, showed that the vast majority of studies
were at high risk of bias and have the potential to overestimate
treatment effects. The methodology for assessing the quality of
studies in a SR continues to be an issue on ongoing debate.
Previous research has identified inherent problems with the use of
summary scores from quality scales, and different scales have been
shown to lead to discordant results [13]. Many scales such as the
Jadad also place undue emphasis on the reporting, rather than the
conduct, of trials. Taken together, these limitations may suggest
that the RoB tool is a more favorable approach for assessing the
internal validity of studies.
The factor that was most influential for risk of bias was the
potential for inappropriate influence of study sponsors. We
included this variable within the ‘‘other sources of bias’’ domain;
however, users of the RoB tool may consider examining this
Figure 1. Mean differences in effect estimates for FEV1 across domains and overall risk of bias (with and without ‘‘other’’ sources of
bias), high/unclear vs. low risk of bias (Note: TE=treatment effect; FEV1=forced expiratory volume in 1 second. Components were
not estimable when all studies were rated the same [i.e., all high/unclear or all low risk of bias]).
doi:10.1371/journal.pone.0017242.g001
Figure 2. Mean differences in effect estimates for FEV1 across domains and overall risk of bias (with and without ‘‘other’’ sources of
bias), high vs. low/unclear risk of bias (Note: treatment effect; FEV1 = forced expiratory volume in 1 second. Components were not
estimable when all studies were rated the same [i.e., all high or all low/unclear risk of bias]).
doi:10.1371/journal.pone.0017242.g002
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and its influence on the design, conduct, and reporting of trials.
Further, we developed our own guidelines to determine whether
there was potential bias due to inappropriate influence of the study
sponsor. Clear and consistent guidelines are needed for other users
of the RoB tool. The majority of reported LABA/ICS trials for
persistent asthma have pharmaceutical industry sponsorship or
include industry employees as authors on the publications. There
is substantial literature supporting the association between
pharmaceutical funding and results favouring the sponsors’
interests [14]. Efforts to ensure separation between the pharma-
ceutical industry and published research therefore appear
warranted and urgently needed.
We were unable to demonstrate a clear association between risk
of bias and effect estimates. This may be a result of several factors.
First, there was considerable homogeneity in treatment effects and
any observed differences were relatively small, therefore it may be
unrealistic to expect differences across sub-groups. Second, there
were few studies in the low risk of bias category which may have
reduced the power to detect differences.
There were several limitations to this study. We explored our
research questions within a SR in order to assess how the RoB tool
performs in the context of a SR. The homogeneity among the
studies and the relatively small sample of studies (n=107) may
have limited our ability to detect differences in effect estimates by
risk of bias. The confidence intervals were wide and do not rule
out the possibility of an association. Moreover, the majority of
studies in this sample showed some potential for influence from
the pharmaceutical industry. We did not follow-up with authors to
confirm conflicts of interest or methods used to ensure separation
between the pharmaceutical industry and researchers during the
conduct, analysis, and reporting of trials; however, when we
removed the funding item from our overall RoB assessments, we
found that risk of bias remained high or unclear for the majority
of studies. Finally, the RoB assessments were not conducted
concurrently or by the same group of reviewers as the Jadad and
allocation concealment assessments. This may have introduced
some variability in the assessments and judgments made.
Conclusion
The Risk of Bias tool is a new, Cochrane-recommended
approach to assessing the internal validity of RCTs. This study
demonstrates that the inter-rater reliability of the tool is enhanced
withappropriatetraining,pilot-testing,andcontext-specificdecision
rules. Clear and consistent decision rules for the Risk of Bias tool
regarding potential influence of the study sponsor are needed. The
low correlation of risk of bias results with other approaches to
assessing methodological quality suggests that the tool is measuring
different constructs, and may be more appropriate to detect threats
to internal validity. The risk of bias assessments did not differentiate
effect estimates in this group of studies; however, the frequent and
intimate involvement of the pharmaceutical industry in this body of
literature should raise concerns about potential overestimates of
treatment effects in favour of the sponsors’ interests.
Figure 3. Mean differences in effect estimates for symptom-free days across domains and overall risk of bias (with and without
‘‘other’’ sources of bias), high/unclear vs. low risk of bias. [Note: TE = treatment effect]).
doi:10.1371/journal.pone.0017242.g003
Figure 4. Mean differences in effect estimates for symptom-free days across domains and overall risk of bias (with and without
‘‘other’’ sources of bias), high vs. low/unclear risk of bias. (Note: TE = treatment effect. Components were not estimable when all studies
were rated the same [i.e., all high or all low/unclear risk of bias]).
doi:10.1371/journal.pone.0017242.g004
Application of the Risk of Bias Tool
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Appendix S1 These decision rules are intended to
supplement the criteria for assessing risk of bias as
presented in the Cochrane Handbook for Systematic
Reviews of Interventions.
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